clinical trial · NCT07557420
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc.·phase3·recruiting·n = 19
NMOSDNeuromyelitis Optica Spectrum DisorderRavulizumab
brief summary
The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).
started
Jul 20, 2026
primary completion
Sep 19, 2028
completion
Sep 19, 2028
last updated
Sep 11, 2026
official title
A Phase 3b, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol